Table 1. Prevalence of Breast Cancer Receptor-Subtypes by Ethnicity, Age, and Tumor Histopathology.
| CHARACTERISTICS |
RECEPTOR-SUBTYPE
|
P-VALUE | |||||||
|---|---|---|---|---|---|---|---|---|---|
| All Cases | HR+/HER2- | HR+/HER2+ | HR-/HER2+ | TNBC | |||||
| N (%) | N (%) | N (%) | N (%) | N (%) | |||||
| 318 (100) | 156 (49.1) | 29 (9.0) | 32 (10.1) | 101 (31.8) | |||||
|
Ethnicity | |||||||||
| African-American | 166 (52.2) | 82 (49.4) | 15 (9.0) | 11 (6.6) | 58 (35.0) | ||||
| Hispanic/Latina | 152 (47.8) | 74 (48.7) | 14 (9.2) | 21 (13.8) | 43 (28.3) | 0.721 | |||
|
Age Characteristics | |||||||||
| Age, mean yrs (SD) | 50.6 (10.2) | 51.7 (10.3) | 51.5 (10.0) | 50.0 (10.1) | 48.8 (10.1) | 0.159 | |||
| Age groups | |||||||||
| < 50 yrs | 153 (48.1) | 65 (42.5) | 14 (9.2) | 15 (9.8) | 59 (38.5) | ||||
| > 50 yrs | 165 (51.9) | 91 (55.2) | 15 (9.1) | 17 (10.3) | 42 (25.4) | 0.011* | |||
| African-American | |||||||||
| < 50 yrs | 68 (41.0) | 30 (44.1) | 7 (10.3) | 2 (3.0) | 29 (42.6) | ||||
| > 50 yrs | 98 (59.0) | 52 (53.1) | 8 (8.2) | 9 (9.2) | 29 (29.5) | 0.185 | |||
| Hispanic/Latina | |||||||||
| < 50 yrs | 85 (55.9) | 35 (41.2 | 7 (8.2) | 13 (15.3) | 30 (35.3) | ||||
| > 50 yrs | 67 (44.1) | 39 (58.2) | 7 (10.4) | 8 (12.0) | 13 (19.4) | 0.015* | |||
|
Tumor Histopathology | |||||||||
| AJCC stage (N = 303) | |||||||||
| 0-I | 69 (22.8) | 40 (26.3) | 9 (31.03) | 7 (22.6) | 13 (14.3) | ||||
| II | 139 (45.9) | 67 (44.1) | 7 (24.14) | 14 (45.2) | 51 (56.0) | 0.220 | |||
| III-IV | 95 (31.3) | 45 (29.6) | 13 (44.83) | 10 (32.2) | 27 (29.7) | ||||
| Tumor size (N = 303) | |||||||||
| <2cm | 95 (31.4) | 54 (35.3) | 10 (34.5) | 10 (33.3) | 21 (23.0) | ||||
| 2cm - 5cm | 126 (41.6) | 68 (44.4) | 7 (24.1) | 9 (30.0) | 42 (46.2) | 0.022* | |||
| >5cm | 82 (27.0) | 31 (20.3) | 12 (41.4) | 11 (36.7) | 28 (30.8) | ||||
| Lymph node (N = 305) | |||||||||
| Positive | 165 (54.1) | 78 (51.0) | 16 (55.2) | 15 (50.0) | 56 (60.2) | 0.199 | |||
| Negative | 140 (45.9) | 75 (49.0) | 13 (44.8) | 15 (50.0) | 37 (39.8) | ||||
| Histology (N=303) | |||||||||
| IDC/ILC | 244 (80.53) | 123 (81.5) | 26 (89.7) | 22 (73.3) | 73 (78.5) | ||||
| DCIS/LCIS | 48 (15.84) | 24 (15.9) | 2 (6.9) | 6 (20.0) | 16 (17.2) | 0.345 | |||
| Inflammatory/other | 11 ( 3.63) | 4 ( 2.6) | 1 (3.4) | 2 ( 6.7) | 4 (4.3) | ||||
| Differentiation (N=298) | |||||||||
| Well | 34 (11.4) | 21 (14.1) | 6 (20.7) | 2 ( 6.7) | 5 (5.6) | ||||
| Moderately | 96 (32.2) | 61 (40.9) | 7 (24.1) | 13 (43.3) | 15 (16.7) | <0.001* | |||
| Poorly | 168 (56.4) | 67 (45.0) | 16 (55.2) | 15 (50.0) | 70 (77.7) | ||||
| Ki67 (N=213) | |||||||||
| Low | 137 (64.3) | 84 (80.8) | 15 (62.5) | 15 (68.2) | 23 (36.5) | <0.001* | |||
| High | 76 (35.7) | 20 (19.2) | 9 (37.5) | 7 (31.8) | 40 (63.5) | ||||
Abbreviations: HR – Hormonal Receptor (Estrogen/Progesterone Receptors), HER2 ( human epidermal growth factor receptor 2), TNBC – Triple Receptor-Negative Breast Cancer (ER-/PR-/HER2-) , SD – Standard Deviation, AJCC –American Joint Committee on Cancer, IDC/ILC – Infiltrating Ductal/Lobular Carcinoma; DCIS/LCIS – Ductal/Lobular Carcinoma In Situ. * P-value < 0.05 is significant.